Advantage of a Narrow Spectrum Host Defense (Antimicrobial) Peptide Over a Broad Spectrum Analog in Preclinical Drug Development

about

Advantage of a Narrow Spectrum Host Defense (Antimicrobial) Peptide Over a Broad Spectrum Analog in Preclinical Drug Development

Item

http://www.wikidata.org/entity/Q58728409

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Advantage of a Narrow Spectrum ...... n Preclinical Drug Development

@en

Advantage of a Narrow Spectrum Host Defense

@nl

type

Item

label

Advantage of a Narrow Spectrum ...... n Preclinical Drug Development

@en

Advantage of a Narrow Spectrum Host Defense

@nl

prefLabel

Advantage of a Narrow Spectrum ...... n Preclinical Drug Development

@en

Advantage of a Narrow Spectrum Host Defense

@nl

P1476

Advantage of a Narrow Spectrum ...... n Preclinical Drug Development

@en

P2093

Carl N Kraus

http://www.w3.org/2001/XMLSchema#string

Eszter Ostorhazi

http://www.w3.org/2001/XMLSchema#string

Laszlo Otvos

http://www.w3.org/2001/XMLSchema#string

Nicole Herth

http://www.w3.org/2001/XMLSchema#string

Ralf Hoffmann

http://www.w3.org/2001/XMLSchema#string

P2860

Structural studies on the forward and reverse binding modes of peptides to the chaperone DnaK

Antimicrobial peptides of multicellular organisms

In vitro and in vivo activities of antimicrobial peptides developed using an amino acid-based activity prediction method

Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use.

Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections.

Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections.

Cytokines, inflammation, and pain.

Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections.

Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment.

Taking inventory: antibacterial agents currently at or beyond phase 1.

P304

359

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FCHEM.2018.00359

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

John D Wade

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30186829

http://www.w3.org/2001/XMLSchema#string

P921

general chemistry

P932

6111444

http://www.w3.org/2001/XMLSchema#string